Experiences of testing immunoglobulins to the SARS-CoV-2 virus in outpatient practice

Abstract

The study aimed to analyze the results of testing the presence of immunoglobulins of severe acute respiratory syndrome coronavirus 2 infection in outpatient clinical practice. The data of all tests of immunoglobulins G and M performed in the laboratory of Polyclinic No. 2 of the Administrative Department of the President of the Russian Federation from June 5 to October 2, 2020, were analyzed. In total, the studies were conducted in 784 applicants (319 [40.7%] men and 465 [59.3%] women), with the average age of 48.46±14.044 years (18 to 89 years). Of patients, 317 were clinically diagnosed with a new coronavirus infection, 64 were examined as having contacted the infected, 83 had bronchopulmonary diseases, and 320 were healthy individuals. A positive test result for the presence of IgG antibodies was obtained in 87.7% of patients with a new coronavirus infection. Of cases, 96.3% had a typical X-ray presentation of viral pneumonia that was confirmed by the polymerase chain reaction method, and also, 5% of cases in the healthy group. The data obtained enabled us to establish high sensitivity of the test systems used.

Keywords

immunoglobulins / SARS-CoV-2 / coronavirus infection / IgM / IgG

References

[1] Devyatkin AV, Devyatkin AA. A novel coronavirus infection – COVID-19. Origin, tropism, transmission, routes, lab diagnostics and specific care. Kremlevskaya meditsina. Klinicheskii vestnik. 2020;(2):5–13. (In Russ). doi: 10.26269/b9ve-xf49.

[2] Девяткин А.В., Девяткин А.А. Новая коронавирусная инфекция – COVID-19. Вопросы происхождения, тропности возбудителя, путей передачи инфекции, лабораторной диагностики и специфической терапии // Кремлевская медицина. Клинический вестник. 2020. № 2. С. 5–13 doi: 10.26269/b9ve-xf49.

[3] Kuvshinova IN, Nekrasov BG, Livitskaya NI, Molodykh SV, Rukavishnikov MYu. Sensitivity and specificity of VEKTOR-BEST JSC reagent kits for the detection of immunoglobulins of different classes in SARS-COV-2. Spravochnik zaveduyushchego KDL. 2020;(10):27–32. (In Russ).

[4] Кувшинова И.Н., Некрасов Б.Г., Ливицкая Н.И., Молодых С.В., Рукавишников М.Ю. Чувствительность и специфичность наборов реагентов АО «ВЕКТОР-БЕСТ» для выявления иммуноглобулинов разных классов в SARS-COV-2 // Справочник заведующего КДЛ. 2020. № 10. С. 27–32.

[5] Kuleshova SV, Grigorieva EV, Mukharaeva AD, Minushkina LO. Experience in determining antibodies to the SARS-COV-2 virus - the causative agent of a new coronavirus infection. Spravochnik zaveduyushchego KDL. 2020;(9):9–15. (In Russ).

[6] Кулешова С.В., Григорьева Е.В., Мухараева А.Д., Минушкина Л.О. Опыт определения антител к вирусу SARS-COV-2 – возбудителю новой коронавирусной инфекции // Справочник заведующего КДЛ. 2020. № 9. С. 9–15.

[7] Balakhonov SV, Dubrovina VI, Chesnokova MV, Voitkova VV, Pyatidesyatnikova AB, Bryukhova DD, et al. Studying humoral immune response at mild and asymptomatic COVID-19 forms. Acta biomedica scientifica. 2020;5(5):26–30. (In Russ). doi: 10.29413/ABS.2020-5.5.3

[8] Балахонов С.В., Дубровина В.И., Чеснокова М.В., Войткова В.В., Пятидесятникова А.Б., Брюхова Д.Д., и др. Изучение гуморального иммунного ответа при лёгкой и бессимптомной формах проявления COVID-19 // Acta biomedica scientifica. 2020. T. 5. № 5. С. 26–30. doi: 10.29413/ABS.2020-5.5.3.

[9] Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, Sun R, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020:1518-1524. doi: 10.1002/jmv.25727.

[10] Li Z., Yi Y., Luo X., Xiong N., Liu Y., Li S., et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis // J Med Virol. 2020. P. 1518-1524. doi: 10.1002/jmv.25727.

[11] Tré-Hardy M, Wilmet A, Beukinga I, Favresse J, Dogné JM, Douxfils J, Blairon L. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA and IgM antibodies. J Med Virol. 2020:803-811. doi: 10.1002/jmv.26303.

[12] Tré-Hardy M., Wilmet A., Beukinga I., Favresse J., Dogné J.M., Douxfils J., Blairon L. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA and IgM antibodies // J Med Virol. 2020. P. 803-811. doi: 10.1002/jmv.26303.

[13] Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol. 2020:2243-2247. doi: 10.1002/jmv.26145.

[14] Kohmer N., Westhaus S., Rühl C., Ciesek S., Rabenau H.F. Clinical performance of different SARS-CoV-2 IgG antibody tests // J Med Virol. 2020. P. 2243-2247. doi: 10.1002/jmv.26145.

[15] Popova AYu, Ezhlova EB, Mel’nikova AA, Bashketova NS, Fridman RK, Lyalina LV, et al. Herd immunity to SARS-CoV-2 among the population in Saint-Petersburg during the COVID-19 epidemic. Problemy osobo opasnykh infektsi. 2020;(3):124–130. (In Russ). doi: 10.21055/0370-1069-2020-3-124-130.

[16] Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Башкетова Н.С., Фридман Р.К., Лялина Л.В., и др. Популяционный иммунитет к SARS-CoV-2 среди населения СанктПетербурга в период эпидемии COVID-19 // Проблемы особо опасных инфекций. 2020. № 3. С. 124–130. doi: 10.21055/0370-1069-2020-3-124-130.

[17] Popova AYu, Ezhlova EB, Mel’nikova AA, Istorik OA, Mosevich OS, Lyalina LV, et al. Assessment of the herd immunity to SARS-CoV-2 among the population of the Leningrad Region during the COVID-19 epidemic. Problemy osobo opasnykh infektsii. 2020;(3):114–123. (In Russ). doi: 10.21055/0370-1069-2020-3-114-123.

[18] Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Историк О.А., Мосевич О.С., Лялина Л.В., и др. Оценкa популяционого иммунитета к SARS-CoV-2 среди населения Ленинградской области в период эпидемии COVID-19 // Проблемы особо опасных инфекций. 2020. № 3. С. 114–123. doi: 10.21055/0370-1069-2020-3-114-123.

RIGHTS & PERMISSIONS

Eco-Vector